An investigational therapy is demonstrating preclinical promise against non-Hodgkin lymphoma by boosting natural killer cells ...

He further explained he was diagnosed with a slow-growing "bone marrow cancer" called Waldenström's macroglobulinemia (WM): ...

Donald Bell, a 74-year-old gay Black man who is co-chair of the Illinois Commission on LGBTQ Aging, lives alone in a studio apartment in subsidized LGBTQ+-friendly senior housing in Chicago. He spent ...

Rachel Drake, pharmacy technician coordinator, University of Kansas Health System, explains how her team collaborates with ...

The holiday season is the perfect time for a good TV binge. Whether you’re regressing to your childhood self or need a break ...

Global Refractory Follicular Lymphoma Diagnostics Market Projected to Reach USD 464.47 Million by 2029 Refractory Follicular ...

An expert from the CURE® advisory board explains the likely treatability of Dave Coulier’s non-Hodgkin lymphoma.

Irvine, California Monday, December 23, 2024, 18:00 Hrs [IST] ...

A haematologist shares insights into the challenges of the disease and the promise of emerging treatment options.

These long-term data support axicabtagene ciloleucel as a highly effective therapeutic approach for patients with relapsed or ...

Diffuse large B-cell lymphoma is the most common type of lymphoma. It makes up approximately 25% of all non-Hodgkin’s lymphomas, which are cancers that lack defining cells called Hodgkin cells ...